LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Ranger Investment Management L.P.

Ranger Investment Management L.P. increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 912,503 shares of the medical instruments supplier’s stock after buying an additional 13,681 shares during the period. LeMaitre Vascular comprises approximately 3.1% of Ranger Investment Management L.P.’s investment portfolio, making the stock its 2nd largest holding. Ranger Investment Management L.P. owned approximately 4.10% of LeMaitre Vascular worth $51,794,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Exchange Traded Concepts LLC grew its holdings in LeMaitre Vascular by 0.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock worth $1,343,000 after acquiring an additional 187 shares during the period. Riverwater Partners LLC lifted its holdings in LeMaitre Vascular by 2.5% during the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after buying an additional 198 shares during the last quarter. Personal CFO Solutions LLC lifted its holdings in shares of LeMaitre Vascular by 6.4% in the 4th quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 336 shares during the last quarter. Swiss National Bank increased its position in LeMaitre Vascular by 1.2% in the 3rd quarter. Swiss National Bank now owns 43,900 shares of the medical instruments supplier’s stock valued at $2,392,000 after acquiring an additional 500 shares during the period. Finally, SRS Capital Advisors Inc. lifted its holdings in shares of LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 524 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 0.4 %

Shares of NASDAQ LMAT traded down $0.31 on Friday, reaching $77.48. 89,248 shares of the company’s stock traded hands, compared to its average volume of 101,074. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $81.68. The business’s 50 day simple moving average is $71.58 and its two-hundred day simple moving average is $63.79. The company has a market cap of $1.74 billion, a price-to-earnings ratio of 51.31, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. During the same period in the previous year, the company posted $0.27 EPS. The firm’s revenue was up 13.6% on a year-over-year basis. Analysts forecast that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Transactions at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bridget A. Ross sold 5,500 shares of LeMaitre Vascular stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $77.99, for a total transaction of $428,945.00. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $177,661.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 8,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The disclosure for this sale can be found here. Insiders sold a total of 87,431 shares of company stock worth $6,627,520 over the last three months. 10.79% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LMAT. Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the company from $59.00 to $75.00 in a research report on Friday, April 26th. Roth Mkm reissued a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. JMP Securities upped their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research note on Friday, May 3rd. Finally, Barrington Research increased their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $77.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.